Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib + Obinutuzumab in R/R CLL/SLL and B-Cell Malignancies
NCT03010358Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entospletinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL). Started Jul 2017; status: completed.
02
Drugs
entospletinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03010358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010358.